Titre : Test pharmacogénomique

Test pharmacogénomique : Questions médicales fréquentes

Termes MeSH sélectionnés :

Probability
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Test pharmacogénomique : Questions médicales les plus fréquentes", "headline": "Test pharmacogénomique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Test pharmacogénomique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-03", "dateModified": "2025-02-26", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Test pharmacogénomique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Dépistage génétique", "url": "https://questionsmedicales.fr/mesh/D005820", "about": { "@type": "MedicalCondition", "name": "Dépistage génétique", "code": { "@type": "MedicalCode", "code": "D005820", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N02.421.726.233.221" } } }, "about": { "@type": "MedicalCondition", "name": "Test pharmacogénomique", "alternateName": "Pharmacogenomic Testing", "code": { "@type": "MedicalCode", "code": "D000071185", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jesse J Swen", "url": "https://questionsmedicales.fr/author/Jesse%20J%20Swen", "affiliation": { "@type": "Organization", "name": "Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands." } }, { "@type": "Person", "name": "Henk-Jan Guchelaar", "url": "https://questionsmedicales.fr/author/Henk-Jan%20Guchelaar", "affiliation": { "@type": "Organization", "name": "Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands." } }, { "@type": "Person", "name": "Jeffrey R Bishop", "url": "https://questionsmedicales.fr/author/Jeffrey%20R%20Bishop", "affiliation": { "@type": "Organization", "name": "Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy and Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA." } }, { "@type": "Person", "name": "James L Kennedy", "url": "https://questionsmedicales.fr/author/James%20L%20Kennedy", "affiliation": { "@type": "Organization", "name": "Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada." } }, { "@type": "Person", "name": "George P Patrinos", "url": "https://questionsmedicales.fr/author/George%20P%20Patrinos", "affiliation": { "@type": "Organization", "name": "University of Patras School of Health Sciences, Department of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy, Patras, Greece." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.", "datePublished": "2022-09-09", "url": "https://questionsmedicales.fr/article/36088952", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/S2352-4642(22)00245-0" } }, { "@type": "ScholarlyArticle", "name": "'I probably wouldn't want to talk about anything too personal': A qualitative exploration of how issues of privacy, confidentiality and surveillance in the home impact on access and engagement with online services and spaces for care-experienced young people.", "datePublished": "2023-10-19", "url": "https://questionsmedicales.fr/article/37873026", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/03085759231203019" } }, { "@type": "ScholarlyArticle", "name": "Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis.", "datePublished": "2022-08-27", "url": "https://questionsmedicales.fr/article/36145549", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/pharmaceutics14091801" } }, { "@type": "ScholarlyArticle", "name": "Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).", "datePublished": "2024-07-14", "url": "https://questionsmedicales.fr/article/39029359", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.lungcan.2024.107894" } }, { "@type": "ScholarlyArticle", "name": "Mandibular dose-volume predicts time-to-osteoradionecrosis in an actuarial normal-tissue complication probability (NTCP) model: External validation of right-censored clinico-dosimetric and competing risk application across international multi-institutional observational cohorts and online graphical user interface clinical support tool assessment.", "datePublished": "2024-08-20", "url": "https://questionsmedicales.fr/article/39228724", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1101/2024.08.20.24312311" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Établissements, main d'oeuvre et services de soins de santé", "item": "https://questionsmedicales.fr/mesh/D005159" }, { "@type": "ListItem", "position": 3, "name": "Services de santé", "item": "https://questionsmedicales.fr/mesh/D006296" }, { "@type": "ListItem", "position": 4, "name": "Services de médecine préventive", "item": "https://questionsmedicales.fr/mesh/D011314" }, { "@type": "ListItem", "position": 5, "name": "Services de diagnostic", "item": "https://questionsmedicales.fr/mesh/D003954" }, { "@type": "ListItem", "position": 6, "name": "Dépistage génétique", "item": "https://questionsmedicales.fr/mesh/D005820" }, { "@type": "ListItem", "position": 7, "name": "Test pharmacogénomique", "item": "https://questionsmedicales.fr/mesh/D000071185" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Test pharmacogénomique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Test pharmacogénomique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Test pharmacogénomique", "description": "Qu'est-ce qu'un test pharmacogénomique ?\nQuand est-il recommandé de faire un test ?\nQuels types de médicaments sont concernés ?\nComment se déroule un test ?\nLes tests sont-ils fiables ?", "url": "https://questionsmedicales.fr/mesh/D000071185?mesh_terms=Probability&page=276#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Test pharmacogénomique", "description": "Quels symptômes peuvent indiquer un besoin de test ?\nLes tests peuvent-ils prédire des symptômes ?\nPeut-on avoir des symptômes sans test ?\nLes symptômes varient-ils selon les gènes ?\nLes tests peuvent-ils aider à diagnostiquer des maladies ?", "url": "https://questionsmedicales.fr/mesh/D000071185?mesh_terms=Probability&page=276#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Test pharmacogénomique", "description": "Les tests peuvent-ils prévenir des effets secondaires ?\nComment intégrer les tests dans la prévention ?\nLes tests sont-ils recommandés pour tous ?\nPeut-on se préparer à un test ?\nLes tests peuvent-ils réduire les coûts de santé ?", "url": "https://questionsmedicales.fr/mesh/D000071185?mesh_terms=Probability&page=276#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Test pharmacogénomique", "description": "Comment les tests influencent-ils les traitements ?\nPeut-on éviter des traitements grâce aux tests ?\nLes tests sont-ils utilisés pour tous les médicaments ?\nLes résultats des tests sont-ils toujours clairs ?\nLes tests peuvent-ils changer en cours de traitement ?", "url": "https://questionsmedicales.fr/mesh/D000071185?mesh_terms=Probability&page=276#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Test pharmacogénomique", "description": "Quelles complications peuvent survenir sans test ?\nLes tests peuvent-ils prévenir des complications ?\nLes complications sont-elles toujours évitables ?\nComment gérer les complications liées aux médicaments ?\nLes complications peuvent-elles affecter le traitement futur ?", "url": "https://questionsmedicales.fr/mesh/D000071185?mesh_terms=Probability&page=276#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Test pharmacogénomique", "description": "Quels facteurs de risque influencent les tests ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes facteurs de risque sont-ils les mêmes pour tous ?\nComment évaluer les facteurs de risque ?\nLes facteurs de risque peuvent-ils changer ?", "url": "https://questionsmedicales.fr/mesh/D000071185?mesh_terms=Probability&page=276#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Qu'est-ce qu'un test pharmacogénomique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "C'est un test qui analyse les gènes pour prédire la réponse aux médicaments." } }, { "@type": "Question", "name": "Quand est-il recommandé de faire un test ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Il est recommandé avant de commencer un traitement médicamenteux, surtout pour certains médicaments." } }, { "@type": "Question", "name": "Quels types de médicaments sont concernés ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les médicaments pour le cancer, les antidépresseurs et les anticoagulants sont souvent testés." } }, { "@type": "Question", "name": "Comment se déroule un test ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Un échantillon de sang ou de salive est prélevé et analysé en laboratoire." } }, { "@type": "Question", "name": "Les tests sont-ils fiables ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, mais leur précision dépend de la qualité du laboratoire et des gènes analysés." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un besoin de test ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des effets secondaires graves ou une réponse inefficace au traitement peuvent le justifier." } }, { "@type": "Question", "name": "Les tests peuvent-ils prédire des symptômes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent aider à anticiper des réactions indésirables à certains médicaments." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes sans test ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains symptômes peuvent survenir sans lien avec la génétique ou les médicaments." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon les gènes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les variations génétiques peuvent influencer la gravité et la nature des symptômes." } }, { "@type": "Question", "name": "Les tests peuvent-ils aider à diagnostiquer des maladies ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Indirectement, en identifiant des prédispositions génétiques à certaines maladies." } }, { "@type": "Question", "name": "Les tests peuvent-ils prévenir des effets secondaires ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils aident à choisir des médicaments moins susceptibles de provoquer des effets indésirables." } }, { "@type": "Question", "name": "Comment intégrer les tests dans la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "En les utilisant lors de la prescription de médicaments pour anticiper les réactions." } }, { "@type": "Question", "name": "Les tests sont-ils recommandés pour tous ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils sont surtout recommandés pour les personnes avec des antécédents médicaux complexes." } }, { "@type": "Question", "name": "Peut-on se préparer à un test ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Il est conseillé de discuter de l'historique médical et des médicaments en cours avec le médecin." } }, { "@type": "Question", "name": "Les tests peuvent-ils réduire les coûts de santé ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en évitant des traitements inefficaces et des hospitalisations dues à des effets secondaires." } }, { "@type": "Question", "name": "Comment les tests influencent-ils les traitements ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Ils permettent de personnaliser les traitements en fonction de la réponse génétique." } }, { "@type": "Question", "name": "Peut-on éviter des traitements grâce aux tests ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en identifiant les médicaments susceptibles de provoquer des effets indésirables." } }, { "@type": "Question", "name": "Les tests sont-ils utilisés pour tous les médicaments ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils sont principalement utilisés pour certains médicaments à haut risque." } }, { "@type": "Question", "name": "Les résultats des tests sont-ils toujours clairs ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Pas toujours, certains résultats peuvent être ambigus et nécessiter une interprétation." } }, { "@type": "Question", "name": "Les tests peuvent-ils changer en cours de traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests supplémentaires peuvent être nécessaires si le traitement échoue." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir sans test ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des effets secondaires graves ou des traitements inefficaces peuvent survenir." } }, { "@type": "Question", "name": "Les tests peuvent-ils prévenir des complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en identifiant les patients à risque de réactions indésirables aux médicaments." } }, { "@type": "Question", "name": "Les complications sont-elles toujours évitables ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Non, certaines complications peuvent survenir malgré un test pharmacogénomique." } }, { "@type": "Question", "name": "Comment gérer les complications liées aux médicaments ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "En ajustant le traitement selon les résultats des tests et en surveillant les effets." } }, { "@type": "Question", "name": "Les complications peuvent-elles affecter le traitement futur ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent influencer les choix de médicaments dans le futur." } }, { "@type": "Question", "name": "Quels facteurs de risque influencent les tests ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'hérédité, les antécédents médicaux et les traitements antérieurs sont des facteurs clés." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'environnement peut interagir avec la génétique et influencer la réponse aux médicaments." } }, { "@type": "Question", "name": "Les facteurs de risque sont-ils les mêmes pour tous ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils varient selon les individus et leurs antécédents médicaux." } }, { "@type": "Question", "name": "Comment évaluer les facteurs de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Par une évaluation médicale complète et des tests génétiques appropriés." } }, { "@type": "Question", "name": "Les facteurs de risque peuvent-ils changer ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent évoluer avec le temps et les traitements reçus." } } ] } ] }

Sources (2756 au total)

Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.

Switching from intravenous antibiotic therapy to oral antibiotic therapy among neonates is not yet practised in high-income settings due to uncertainties about exposure and safety. We aimed to assess ... In this multicentre, randomised, open-label, non-inferiority trial, patients were recruited at 17 hospitals in the Netherlands. Neonates (postmenstrual age ≥35 weeks, postnatal age 0-28 days, bodyweig... Between Feb 8, 2018 and May 12, 2021, 510 neonates were randomly assigned (n=255 oral amoxicillin-clavulanic group; n=255 intravenous antibiotic group). After excluding those who withdrew consent (n=4... An early intravenous-to-oral antibiotic switch with amoxicillin-clavulanic acid is non-inferior to a full course of intravenous antibiotics in neonates with probable bacterial infection and is not ass... The Netherlands Organization for Health Research and Development, Innovatiefonds Zorgverzekeraars, and the Sophia Foundation for Scientific Research....

'I probably wouldn't want to talk about anything too personal': A qualitative exploration of how issues of privacy, confidentiality and surveillance in the home impact on access and engagement with online services and spaces for care-experienced young people.

This paper draws on a qualitative interview-based study that explored online mental health and wellbeing interventions and services for care-experienced young people. The study involved young people (...

Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).

The risk and survival of patients with non-small cell lung cancer (NSCLC) with pre-existing autoimmune disorders (AIDs) receiving immune checkpoint blockade (ICB) therapy have not been clearly establi... This multi-institutional, retrospective cohort study was conducted in collaboration with 20 centers in Japan.... In total, 229 patients with advanced or recurrent NSCLC and pre-existing AID, with or without ICB treatment from January 2010-February 2020, were included and analyzed. Among 69 patients who received ... These findings revealed a novel risk factor for AID flares following ICB treatment, that is the diagnosis of NSCLC within 1 year of AID diagnosis, and showed that ICBs may improve survival in this pop...

Mandibular dose-volume predicts time-to-osteoradionecrosis in an actuarial normal-tissue complication probability (NTCP) model: External validation of right-censored clinico-dosimetric and competing risk application across international multi-institutional observational cohorts and online graphical user interface clinical support tool assessment.

Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has impo... Demographic, clinical and dosimetric data were retrospectively obtained for a clinical observational cohort of 1129 patients with HNC treated with radiotherapy (RT) at The University of Texas MD Ander... Our model identified that each unit increase in D25% is significantly associated with a 12% shorter time to ORNJ (Adjusted Time Ratio [ATR] 0·88, p<0·005); pre-RT dental extractions was associated to ... This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose not only on the proba... This work was supported by various funding sources including NIH, NIDCR, NCI, NAPT, NASA, BCM, Affirmed Pharma, CRUK, KWF Dutch Cancer Society, NWO ZonMw, and the Apache Corporation....

The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) Trial: study protocol for a multi-country, multi-centre, double-blind, three-arm, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at high probability of late preterm birth in hospitals in low- resource countries.

Preterm birth complications are the leading cause of newborn and under-5 mortality. Over 85% of all preterm births occur in the late preterm period, i.e. between 34 and < 37 weeks of gestation. Antena... WHO ACTION III trial is a parallel-group, three-arm, individually randomized, double-blind, placebo-controlled trial of two ACS regimens: dexamethasone phosphate 4 × 6 mg q12h or betamethasone phospha... This trial will evaluate the benefits and possible harms of ACS when used in women likely to have a late preterm birth. It will also evaluate a lower-dose ACS regimen based on literature from pharmaco... ISRCTN11434567 . Registered on 7 June 2021....